About this trial
This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.
Eligibility criteria
Qualifiers
Male or female in good general health at 18 to 70 years of age.
Presence of unilateral or bilateral non-infectious uveitis affecting the posterior segment
Patients have active inflammation before Yutiq treatment. Subject meets at least 1 of the following criteria: 1. ≥1+ anterior chamber cell and/or ≥1+ vitreous haze. 2. Fluorescein angiography demonstrates leakages. 3. OCT images showing the macular edema. 4. The times of relapse in one year are equal to or greater than 3.
Steroids and immunosuppressive agents were discontinued within 3 months after Yutiq injection.
Disqualifiers
Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.
Subject with a history of neurologic symptoms suggestive of central nervous system demyelinating disease.
Prior intravitreal treatment with Retisert®, ILUVIEN®, or YUTIQ® (0.18 mg) within 36 months prior to Day 1.
Prior intravitreal treatment with OZURDEX® within 12 weeks prior to Day 1. Prior intravitreal treatment with Triesence® or TRIVARIS™ (triamcinolone) within 12 weeks prior to Day 1.
Trial design
Treatments tested in this trial
- Yutiq